The Use of Air Cleaners to Mitigate Cardiopulmonary Health Impact of Indoor Exposure to Particles and Phthalates

Inflammation Clinical Trial

Official title:

An Interventional Study on the Use of Air Cleaners to Mitigate Cardiopulmonary Health Impact of Indoor Exposure to Particles and Phthalates in Healthy Adults: a Randomized Double-blinded Crossover Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03500614
• Other study ID #: 2017095
• Secondary ID: 2017YFC021160120
• Status: Completed
• Phase: N/A
• Start date: November 14, 2017
• Est. completion date: December 1, 2018

Study information

• Verified date: October 2021
• Source: Peking University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate whether a short-term intervention strategy using air cleaner reduces indoor exposure to airborne particles (particulate matter with an aerodynamic diameter ≤2.5μm, PM2.5) and phthalates and improves cardiopulmonary health among Chinese healthy adults based on a randomized double-blinded crossover trial.

Description:

The randomized double-blind crossover trial includes two cohorts with different intervention and health examination settings and will be conducted in Beijing, China between November 2017-May 2018. The first cohort plans to include 70 healthy college students who live in school dormitories, which were randomized into two dormitory groups to receive either true or sham air cleaner treatment for 1 week and then alternate the treatment after a wash out interval of at least 2 weeks (But in the enrollment, only 57 students were recruited actually). All participants and research staff are blinded to the group assignment. All participants are encouraged to stay in the dormitory with windows/doors tightly closed throughout the 1-week treatment period as far as possible, whereas necessary outdoor activities such as attending classes and dining in school canteens are allowed. All interventions will start at noon on Tuesday or Thursday and continue to the next morning of Tuesday or Thursday to avoid issues related to diurnal variation. Real-time PM2.5 concentrations will be measured using portable monitors and airborne PM2.5 mass samples will be collected in air filters throughout the treatment period. Air and fine particle phase phthalates samples will be collected using glass sampling tube filled with XAD2 macroporous resin and PM2.5 air filters respectively during the last day (24 hours) of the treatment period. Health variables, including blood pressure, lung function, fractional exhaled nitric oxide (FeNO), will be evaluated and biological samples including morning urine and fasting blood will be collected immediately after the completion of each treatment period. Efficacy of air cleaner treatment to reduce indoor exposure to particles and phthalates and related improvements in cardiopulmonary health variables will be evaluated using professional statistical methods. The second cohort plans to include 30 healthy college students who will undergo extended treatment period covering the start, peak and end phases of smog episodes occurring in Beijing (To avoid dropout, 32 students were initially recruited). All interventions will start from the beginning to the end of typical smog episodes. PM2.5 exposure monitoring as detailed above will be performed throughout the treatment period and repeated health examinations will be conducted at time points corresponding to the start, peak and end phases of the smog episodes. Efficacy of air cleaner treatment to reduce indoor exposure to PM2.5 and related improvements in cardiopulmonary health variables throughout the smog episodes will be evaluated using professional statistical methods.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 57
• Est. completion date: December 1, 2018
• Est. primary completion date: April 23, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Healthy college students aged between 18 and 30 years old;
• Will stay within the central urban area of Beijing over the entire study including the wash-out period;
• BMI <30 kg/m3.

Exclusion Criteria:

• Current or ever smokers;
• A history of chronic respiratory diseases;
• A history of chronic cardiovascular diseases;
• Acute infections;
• Medication use in recent one month;
• Leave Beijing during the intervention.

Related Conditions & MeSH terms

• Blood Pressure
• Inflammation
• Lung Function
• Oxidative Stress

Intervention

Behavioral:
• Air cleaner use method 1
All interventions in the first cohort will start at noon on Tuesday or Thursday and continue to the next morning of Tuesday or Thursday.
• Air cleaner use method 2
All interventions in the second cohort will start from the beginning to the end of smog episodes.

Locations

Country	Name	City	State
China	Department of Occupational & Environmental Health Sciences, School of Public Health, Peking University	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood pressure (BP) (cohort 1)	The upper arm BP including both systolic pressure and diastolic pressure will be measured using an Omron J12 electronic sphygmomanometer for three times and the second and third readings will be used.	through the study completion, an average of 1-week
Primary	Lung function (cohort 1)	Lung function measures including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow (PEF) will be determined using a Pony FX spirometer.	through the study completion, an average of 1-week
Primary	Fractional exhaled nitric oxide (FeNO) (cohort 1)	FeNO levels will be measured using a portable NIOX VERO machine (Aerocrine AB, Solna, Sweden).	through the study completion, an average of 1-week
Primary	Urinary oxidative biomarkers (cohort 1)	Morning urine samples will be collected and measured for malondialdehyde (MDA) and 8-iso-prostaglandinF2a (8-iso-PGF2a) using high performance liquid chromatography-mass spectrometry (HPLC-MS) and 8-hydroxydeoxyguanosine (8-OHdG) using enzyme linked immunosorbent assay (ELISA).	through the study completion, an average of 1-week
Primary	Circulating cytokine and chemokine biomarkers (cohort 1)	Peripheral blood samples will be collected and measured for soluble CD40L(sCD40L), epidermal growth factor(EGF), Eotaxin-1, fibroblast growth factor 2(FGF2), fms-related tyrosine kinase 3 ligand(FLT3LG), Fractalkine, granulocyte-colony stimulating factor(G-CSF), granulocyte-macrophage colony-stimulating factor(GM-CSF), growth-related oncogene a(GROa), interferon-a2(IFN-a2), IFN-?, interleukin-1a(IL-1a), IL-1ß, IL-1R1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12, IL-13, IL-15, IL-17, interferon-inducible protein-10(IP-10), monocyte chemoattractant protein-1(MCP-1), MCP-3, macrophage-derived chemokine(MDC), macrophage inflammatory protein-1a(MIP-1a), MIP-1ß, platelet-derived growth factor-AA(PDGF-AA), PDGF-AB/BB, regulated upon activation normal T-cell expressed and secreted(RANTES), transforming growth factor-a(TGF-a), tumor necrosis factor-a(TNF-a), TNF-ß and vascular endothelial growth factor(VEGF) using a liquid chip in Luminex platform.	through the study completion, an average of 1-week
Primary	Inflammatory and immune markers for peripheral blood mononuclear cell (PBMC) (cohort 1)	The following inflammatory and immune markers of PBMC will be measured using labeled antibodies in multiplexed mass cytometry: p53, phospho-p53 (p-p53), p-mitogen-activated protein kinase 1/2 (pErk1/2), cell devision cycle protein 2 (cdc2), p-cdc2, signal transducer and activator of transcription 3 (STAT3), p-STAT3, serine/threonine kinase 1, ataxia telangiectasia mutated (ATM), p-ATM, p62, mammalian target of rapamycin (mTOR), p-mTOR, mitogen-activated protein kinases1+2, nuclear factor-kappa B p65 (NF-?B p65), p-NF-?B p65, c-Jun N-terminal kinase (JNK), p-JNK, glycoprotein 130 (gp130), p-gp130, Cyclin B1, p-Cyclin B1, phosphorylation protein kinase B, autophagy related gene 5, cluster differentiation antigen 4 (CD4), CD8, CD11c, CD14, CD20, CD56, toll-like receptor 4, myeloid differentiation primary response 88, TNF receptor associated factor 6, and interleukin-1 receptor-associated kinase 4.	through the study completion, an average of 1-week
Primary	Change in blood pressure from baseline to during and after the intervention (cohort 2)	The upper arm BP including both systolic pressure and diastolic pressure will be measured using an Omron J12 electronic sphygmomanometer for three times and the second and third readings will be used.	before, during and after the smog episodes (up to 10 days)
Primary	Change in lung function from baseline to during and after the intervention (cohort 2)	Lung function measures including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow (PEF) will be determined using a Pony FX spirometer.	before, during and after the smog episodes (up to 10 days)
Primary	Change in fractional exhaled nitric oxide (FeNO) from baseline to during and after the intervention (cohort 2)	FeNO levels will be measured using a portable NIOX VERO machine (Aerocrine AB, Solna, Sweden).	before, during and after the smog episodes (up to 10 days)
Primary	Change in urinary oxidative biomarkers from baseline to during and after the intervention (cohort 2)	Morning urine samples will be collected and measured for malondialdehyde (MDA) and 8-iso-prostaglandinF2a (8-iso-PGF2a) using high performance liquid chromatography-mass spectrometry (HPLC-MS) and 8-hydroxydeoxyguanosine (8-OHdG) using enzyme linked immunosorbent assay (ELISA).	before, during and after the smog episodes (up to 10 days)
Primary	Change in circulating cytokine and chemokine biomarkers from baseline to during and after the intervention (cohort 2)	Peripheral blood samples will be collected and measured for soluble CD40L(sCD40L), epidermal growth factor(EGF), Eotaxin-1, fibroblast growth factor 2(FGF2), fms-related tyrosine kinase 3 ligand(FLT3LG), Fractalkine, granulocyte-colony stimulating factor(G-CSF), granulocyte-macrophage colony-stimulating factor(GM-CSF), growth-related oncogene a(GROa), interferon-a2(IFN-a2), IFN-?, interleukin-1a(IL-1a), IL-1ß, IL-1R1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12, IL-13, IL-15, IL-17, interferon-inducible protein-10(IP-10), monocyte chemoattractant protein-1(MCP-1), MCP-3, macrophage-derived chemokine(MDC), macrophage inflammatory protein-1a(MIP-1a), MIP-1ß, platelet-derived growth factor-AA(PDGF-AA), PDGF-AB/BB, regulated upon activation normal T-cell expressed and secreted(RANTES), transforming growth factor-a(TGF-a), tumor necrosis factor-a(TNF-a), TNF-ß and vascular endothelial growth factor(VEGF) using a liquid chip in Luminex platform.	before, during and after the smog episodes (up to 10 days)
Secondary	DNA methylation (cohort 1)	Genomic DNA methylation changes associated with indoor exposures will be screened using methylation chip in a group of selected participants and confirmed in both cohorts using bisulfite-polymerase chain reaction-pyrosequencing.	through the study completion, an average of 1-week
Secondary	Concentrations of urinary phthalate metabolites (cohort 1)	Fifteen main phthalate metabolites in morning urine samples including dimethyl phthalate (DMP), diethylphthalate (DEP), diisobuylphthalate (DIBP), dibutyl phthalate (DBP), bis(2-Methoxyethyl)phthalate (DMEP), bis(4-Methyl-2-pentyl)phthalate (DMPP), bis(2-Ethoxyethyl)phthalate (DEEP), dipentyl phthalate (DPP), dihexyl phthalate (DHP), benzyl butyl phthalate (BBP), bis(2-n-butoxyethyl)phthalate (DBEP), dicyclohexyl phthalate (DCHP), bis(2-Ethylhexyl)phthalate (DEHP), di-n-octyl phthalate (DnOP), dinonyl phthalate (DNP) will be quantified using gas chromatography-mass spectrometry (GC-MS).	through the study completion, an average of 1-week
Secondary	Change in DNA methylation from baseline to during and after the intervention (cohort 2)	Genomic DNA methylation changes associated with indoor exposures will be screened using methylation chip in a group of selected participants and confirmed in both cohorts using bisulfite-polymerase chain reaction-pyrosequencing.	before, during and after the smog episodes (up to 10 days)